Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,830.00
-200.00 (-3.32%)
At close: Jan 30, 2026
-14.39%
Market Cap139.38B -15.5%
Revenue (ttm)252.20B +4.9%
Net Income2.37B -51.9%
EPS98.86 -52.1%
Shares Out23.91M
PE Ratio58.97
Forward PEn/a
Dividend50.00 (0.86%)
Ex-Dividend DateDec 27, 2024
Volume68,051
Average Volume67,431
Open6,030.00
Previous Close6,030.00
Day's Range5,780.00 - 6,030.00
52-Week Range4,755.00 - 7,160.00
Beta0.84
RSI49.23
Earnings DateAug 14, 2025

About Kyongbo Pharmaceutical

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research an... [Read more]

Sector Healthcare
Founded 1987
Country South Korea
Stock Exchange Korea Stock Exchange
Ticker Symbol 214390
Full Company Profile

Financial Performance

In 2024, Kyongbo Pharmaceutical's revenue was 238.56 billion, an increase of 10.26% compared to the previous year's 216.36 billion. Earnings were 4.64 billion, an increase of 55.98%.

Financial Statements